← All trials
NCT04489797
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2020
- Primary completion
- Aug 28, 2020
- Completion date
- Aug 28, 2020
- First posted
- Jul 28, 2020
- Last posted
- Oct 30, 2020
- Enrollment
- 35
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Anaheim Clinical TrialsOverall official - principal investigator
- Acerta PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.